A solution to advanced and recurrent cases of endometriosis : FDA approves Immunotherapy for endometrial cancer


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
The FDA is granted accelerated approval to Jemperli (dostarlimab)) for treatment of patients with recurrent and advanced endometrial cancer that has progressed with the prior treatment with the chemotherapy.

Uterine or endometrial cancer originates in the layers of cells in the uterus lining called the endometrium and involves uncontrolled or unregulated growth of cells to form cancerous tumours. Uterine cancer develops in the layers of cells that line the uterus. The lining of the uterus is called the endometrium which is why this condition is also known as endometrial cancer. Uterine cancer is the most common genital cancer and fourth most common cause of cancer. Upto 3 million people are diagnosed with uterine or endometrial cancer every year.

Types of endometrial cancer 

There are two main types of cancer that form in the endometrium which are as follows:

Endometrial adenocarcinomas: This cancer originates in the secreting tissue and one of the most common types of cancer 

Uterine sarcomas: This is the less common form of carcinoma of the uterus and originates in the connective tissue or the muscles of the uterus. 

Endometrial cancer is often detected at an early stage and has a high cure and success rate. Good chances of improvement are seen if Endometrial cancer is detected before it spreads to the entire uterus. 

Causes of endormetrial cancer 

All cancers develop when an uncontrolled group of cells divide abnormally and multiplies in the body at a faster rate forming a tumour. As most of the cancer, doctors and researchers are unable to determine the main cause of endometrial cancer. There is some problem associated with the immune system where it is weakened thus affecting the body overall health causing weight loss and fever. There are some risk factors which are very important and likely contribute to endometrial cancer. They include: 

Obesity:Excess body fat spikes estrogen levels in women and correlates to high cancer risk. 

Never been pregnant: Women who have never given birth to any child for unexplained reasons are also likely and have higher risk of developing endometrial cancer.

Late menopause : Women who begin menopause after 55 years of age are at higher risk of endometrial cancer. This could be due to fluctuating levels of estrogens in women making them more prone to endometrial cancer.

Early puberty : Women who develop early menarche are at higher risk of having endometrial cancer and should take necessary precautions of fluctuating hormonal level. 

Hereditary :Women with genetics of endometrial cancer have increased chances of contracting endometrial cancer 

 Symptoms of endometrial cancer 

Heavy abnormal bleeding  Pain in the abdomen Postmenoupasudal bleeding  Abnormal and irregular periods Prolonger bleeding  Unexpected weight loss  Pelvic pain  Painful sex 

Diagnosis 

Ultrasonography of Abdomen Pelvis  Biopsy of sample tissue to confirm cancer  Hysteroscopy 

Treatment of endometrial cancer 

Total hysterectomy- removal of uterus, cervix, fallopian tubes, ovaries  Chemotherapy  Radiation  Hormonal treatment 

Treatment plans may differ from patient to patient and depends on the stage of cancer and here the patient wants to maintain fertility. 

FDA approves Immunotherapy for endometrial cancer with specific biomarker

On April 22, 2021, FDA approved the Jemprili, which works by targeting the cellular pathway. Jempreli helps the body’s immune system to help fight against the cancer cells by blocking the pathway. The safety and efficacy of Jempreli for endometrial cancer has been evaluated by FDA to expand its progress and treatment in precision medicines. 

A clinical trial was conducted for Jemprili on patients suffering from endometrial cancer. 71 patients with recurrent or advanced endometrial cancer received Jempreli showed complete or partial response with shrinkage of tumour which is effective in case of endometrial cancer patients. This immunotherapy is specifically targeted for endometrial cancer and leverages scientific knowledge surrounding the mechanism of immunotherapy response in this unmet medical need population. 

Tags : #FDA #endometrialcancer #myhealth #medicircle #Jemperli

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

What Happens to Your Body During an All-Nighter?August 06, 2026
Childhood Obesity in India: A Growing Public Health Crisis That Demands Urgent AttentionAugust 06, 2026
Screen Time Effects on Children: What Every Indian Parent and Paediatrician Needs to KnowAugust 06, 2026
Kidney Transplant Recipient Defeats CancerAugust 05, 2026
Fermenta Biotech Lists on India’s National Stock ExchangeAugust 05, 2026
Asia Pacific leaders warn attacks against health and gender are undoing decades of progressAugust 05, 2026
Understanding Long-Term Impacts of Air Purification on ImmunityAugust 05, 2026
Understanding Epigenetics: How Lifestyle Changes Your DNAAugust 05, 2026
CARE Hospitals to Offer Free Vascular Health Check on National Vascular DayAugust 05, 2026
Breastfeeding Myths That New Mothers Should Stop BelievingAugust 05, 2026
Why Modern Lifestyle Causes Chronic InflammationAugust 05, 2026
Endometriosis Awareness: Understanding the Silent Condition Affecting Millions of Indian WomenAugust 05, 2026
A Complete Guide to Pregnancy Health Tips for Indian Women: Nutrition, Wellness, and What Every Expectant Mother Should KnowAugust 05, 2026
Metropolis Healthcare reports strong Q1FY27 performance, with revenue up 17% to ₹450 crore and EBITDA up 27% YoYAugust 04, 2026
India's Silent Liver Health Crisis: New Data Points to Urgent Need for Screening and PreventionAugust 04, 2026
Eureka Forbes Launches 'Ghar Ka New Favourite' Campaign showcasing Forbes SmartClean Robotic Vacuum Cleaner with Shraddha KapoorAugust 04, 2026
Why Preventive Healthcare for Children Is One of the Most Important Investments India Can MakeAugust 04, 2026
The Role of Pathology in Healthcare: From Diagnosis to Disease PreventionAugust 04, 2026
Pathophysiology of Psoriatic Arthritis: Clinical Presentation, Joint Damage Mitigation, and BiologicsAugust 04, 2026
Comprehensive Evaluation of Syncope: Cardiac vs. Neurological Origin WorkupsAugust 04, 2026